譽衡藥業(002437.SZ):2022年佔公司營收比例最高的品種為注射用12種複合維生素
格隆匯7月4日丨譽衡藥業(002437.SZ)近期在接待機構調研時表示,2022年,佔公司營業收入比例最高的品種為注射用12種複合維生素,該產品具備一定的技術壁壘和工藝複雜性,系國產獨家品種,在同類產品市場中保持80%以上的市場份額。
氯化鉀緩釋片2021年中選第五批全國藥品集中採購,產品的醫療機構覆蓋率及銷量進一步提升,根據米內網發佈的2022年全國公立醫院數據,該產品市場份額已提高至30%以上,處於細分市場第二位。
心腦血管領域主要產品有安腦丸/片、銀杏達莫注射液、注射用磷酸肌酸鈉及公司推廣的奧美沙坦酯氨氯地平片、甲苯磺酸艾多沙班片、普伐他汀鈉片等產品。其中,根據米內網發佈的2022年全國公立醫院數據,銀杏達莫注射液的市場份額達30%以上,僅次於益佰製藥。2022年,公司推廣的第一三共的產品覆蓋醫院數量及銷量進一步提升。
公司骨科領域產品有鹿瓜多肽注射液、玻璃酸鈉注射液。鹿瓜多肽注射液近兩年的銷售收入較穩定,細分市場領域中位於第一位。抗腫瘤領域,公司有注射用左亞葉酸鈣、注射用環磷酰胺、注射用鹽酸平陽黴素等產品,佔公司營收的比重不是很大。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.